ASCO GU 2021: ACE inhibitors associated with superior responses in bladder cancer
A retrospective analysis found that in patients with muscle-invasive bladder cancer (MIBC)...
ASCO GU 2021
ASCO GU 2021: Lutetium-177 offers a promising new therapy for metastatic prostate cancer
Radionuclide therapy directed towards prostate-specific membrane antigen (PSMA) demonstrated promising results in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC) [1]. A phase 2 trial compared...
ASCO GU 2021: Axitinib offers hope for improving renal cell cancer surgical outcomes
Tyrosine kinase inhibitor axitinib elicited a 31% response rate in a phase 2 clinical trial that...
ASCO GU 2021: New therapeutic option for early metastatic testicular seminoma
A phase 2 trial demonstrated encouraging outcomes from retroperitoneal lymph node dissection...
ASCO GU 2021: Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
A team of researchers reported that socioeconomic, racial/ethnic, and gender factors influence the...
ASCO GU 2021: Reduced radiation exposure in testicular seminoma surveillance is possible
MRI is non-inferior to CT for the surveillance of stage 1 testicular seminoma. Over a 6-year...
ASCO GU 2021: Better allocation of research dollars needed
Of nearly 80,000,000 USD in funding for bladder cancer research between 2017 and 2019,...
ASCO GU 2021: Superior clinical outcomes and quality of life with nivolumab plus cabozantinib in renal cell cancer
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
ASCO GU 2021: Prognosis of penile cancer associated with HPV status
Determination of human papillomavirus (HPV) status should be done routinely at diagnosis of penile...
ASCO GU 2021: Exploring a new strategy for metastatic germ cell tumors
Cure rates for patients with poor- and intermediate-risk metastatic germ cell tumors lag behind...
ASCO GU 2021: Enfortumab vedotin as treatment option for bladder cancer
Interim data from a clinical trial investigating the efficacy of enfortumab vedotin (EV) on...
ASCO GU 2021: New standard of care recommended for upper tract urothelial cancer
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...
